TYRA · Tyra Biosciences, Inc.

Tyra Biosciences' Q1 2026 results reflect accelerated investment in its lead asset dabogratinib under the '3x3' strategy targeting LG-UTUC (SURF303), IR NMIBC (SURF302), and ACH (BEACH301). R&D expenses rose 34% year-over-year to $33.5M, primarily from ongoing SURF302/BEACH301 trials and SURF303 startup, plus headcount expansion, while G&A increased 23% to $8.5M on personnel costs. This drove net loss up 40% to $39.3M. Despite higher burn, the balance sheet strengthened significantly with $147.9M net proceeds from an ATM offering of 4.7M shares, boosting cash to $383.5M and extending runway into 2H 2028 without near-term dilution pressure. CEO Todd Harris emphasized data-driven alignment with patient journeys in FGFR3-driven diseases, highlighted by first SURF303 patient dosing—a potential registrational study for TYRA's inaugural NDA. CMO Doug Warner noted dabogratinib's potential as a QD oral alternative to procedure-based therapies in urologic cancers and transformative early inhibition in ACH, supported by recent preclinical data on prenatal/postnatal dosing delaying synchondroses fusion. Investors should monitor upcoming catalysts: SURF302 three-month complete response data in August 2026 (>20 patients enrolled) and BEACH301 safety sentinel results in Q4 2026 (four dose levels cleared, no notable safety events). The April board addition of Habib Dable, ex-Acceleron CEO with blockbuster launch expertise (e.g., EYLEA), bolsters commercial readiness as TYRA eyes multiple pivotal readouts.